ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial–mesenchymal transition
Authors:
- 1 July 2016
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 377 (2) , 140-148
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activationOncotarget, 2015
- Treatment of intermediate-stage hepatocellular carcinomaNature Reviews Clinical Oncology, 2014
- Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systemsJournal of Pharmacy and Pharmacology, 2013
- Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinomaOncology Reports, 2012
- Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR InhibitionLiver Cancer, 2012
- NDR2 Acts as the Upstream Kinase of ARK5 during Insulin-like Growth Factor-1 SignalingJournal of Biological Chemistry, 2006
- Regulation of caspase-6 and FLIP by the AMPK family member ARK5Oncogene, 2004
- ARK5 Is a Tumor Invasion-Associated Factor Downstream of Akt SignalingMolecular and Cellular Biology, 2004
- ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiationOncogene, 2003
- Identification of a Novel Protein Kinase Mediating Akt Survival Signaling to the ATM ProteinJournal of Biological Chemistry, 2003